The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize procedures to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.

**DESCRIPTION OF THE EVIDENCE COLLECTION METHOD**
This guideline followed the standard of a systematic review with evidence retrieval based on evidence-based medicine (EBM), so that clinical experience is integrated with the ability to critically analyze and apply scientific information rationally, thus improving the quality of medical care.

We used the structured mode of formulating questions synthesized by the acronym PICO, where P stands for patients with prostate cancer, I stands for indicator, i.e., radium-223, and O stands for outcome, which is benefit.

Based on the structured question, we identified the descriptors that formed the basis of the search for evidence in the databases: Medline-Pubmed. Ninety-nine (99) studies were retrieved and, after applying the eligibility criteria (inclusion and exclusion), 13 were selected to answer the clinical question (Annex I).

**CLINICAL QUESTION**
What is the benefit of radium-223 therapy in prostate cancer?

**GRADES OF RECOMMENDATION AND LEVELS OF EVIDENCE**
- **A**: Experimental or observational studies of higher consistency.
- **B**: Experimental or observational studies of lower consistency.
- **C**: Cases reports / non-controlled studies.
- **D**: Opinion without critical evaluation, based on consensus, physiological studies or animal models.

**OBJECTIVE**
The aim of this guideline is to estimate the benefit of radium-223 chloride therapy (Ra223) in patients with prostate cancer resistant to castration and bone metastases.

**INTRODUCTION**
Ra223 has been approved by the Brazilian Health Surveillance Agency (Anvisa) to be used as a drug in the treatment of patients with bone metastases from metastatic castration-resistant prostate cancer (mCRPC) without known visceral metastases.

This treatment is indicated when patients with mCRPC have blastic bone metastases in an attempt to increase survival, but it is also applied in these conditions when patients have symptoms, such as pain (but not exclusively).

Ra223 is a low-range (< 100 μm), high-energy (27.4 MeV) alpha particle emitter, similar to calcium, which is directed to areas where bone remodeling is increased, which occurs in sclerotic bone metastases of prostate cancer. The high energy of alpha particles causes the DNA to break down in the metastatic cells (cytotoxic effect), with low damage in the adjacent cells due to their low reach (< 10 cells).
DATA EXTRACTION

Survival

After evaluating 64 mCRPC patients eligible for radiation therapy due to bone pain, with mean follow-up time of 18 months, there was greater survival among patients treated with Ra223 (50 kBq/kg dosage) compared to a placebo. Median survival was 65.3 versus 46.4 weeks, respectively, significantly higher for Ra223 (50 kBq/kg dosage) (p=0.006) compared to a placebo (HR=2.12, 95CI 1.12-3.98; p=0.020), indicating a higher risk of death for the placebo group.\(^5\) (A) After 2 years of follow-up of these patients, the median survival of the Ra223-treated group was 71 weeks versus 46.4 weeks in the placebo group (HR=0.445, 95CI 0.232-0.851).\(^6\) (A)

In the largest phase III multicenter controlled randomized trial evaluating 921 mCRPC patients, 614 received six injections of Ra223 (50 kBq/Kg dosage) and 307 received placebo injections. Those patients treated with Ra223 had greater survival compared to those treated with placebo, with a median survival of 14.9 versus 11.3 months. The absolute increase in survival was 10.5 months (95CI 3.3-17.7). In this case, it is necessary to treat nine patients to have an increase in survival of 3.6 months (on average) in one patient.\(^7\) (A)

When this same population was stratified according to prior use of docetaxel, Ra223 continued to show an increase in survival, both in the group of prior use (HR=0.70, 95CI 0.56-0.88; p=0.002) compared to the group that had never used docetaxel (HR=0.69, 95CI 0.52-0.92; p=0.01).\(^6\) (A)

Bone event

In an initial study with 64 mCRPC patients, there was longer time until the first bone event in the Ra223-treated group compared to the placebo group (14 weeks versus 11 weeks) (HR=1.75, 95CI 0.96-3.19; p=0.065). However, there was no significant difference in the number of bone events (p=0.625).\(^3\) (B)

In the large ALSYMPCA study, evaluating 921 patients with mCRPC, patients treated with Ra223 had longer time until the first bone event compared to the placebo group. Median time until the first bone event was 15.6 months with Ra223 versus 9.8 months with a placebo (HR=0.66, 95CI 0.52-0.83; p<0.001).\(^3\) (A)

The data from the above study were further analyzed, focusing exclusively on the skeletal events of the mCRPC population.\(^7\) (A) The authors demonstrated that symptomatic skeletal events occurred in 33% of patients in the Ra223 group and 38% in the placebo group. The Ra223 group required less use of radiotherapy to treat pain (HR=0.67, 95CI 0.53-0.85) and presented a lower spinal compression rate (HR=0.52, 95CI 0.29-0.93). Despite this, the use of Ra223 did not significantly reduce the risk of occurrence of bone events (HR=0.62, 95CI 0.35-1.09) nor the risk of surgical interventions (HR=0.72, 95CI 0.28-1.82).\(^7\) (A)

Another study stratified the population described above according to prior use of docetaxel or not. 352 patients who used docetaxel prior to Ra223 were evaluated versus 262 patients who used only Ra223. There was a reduction in time until the first bone event only in the group of patients taking Ra223 who had previously used docetaxel (p=0.0009).\(^6\) (A)

DOSE TOXICITY AND SAFETY

In the initial randomized controlled multicenter phase II trial of 64 mCRPC, with patients divided into Ra223 and placebo groups, there was no significant difference in hematological toxicity. In addition, no patient discontinued treatment for this reason.\(^1\) (A)

The use of different doses of Ra223 (5 kBq/kg in 26 patients; 25 kBq/kg in 25 patients; 50 kBq/kg in 25 patients; 100 kBq/kg in 24 patients) in 100 mCRPC patients showed no difference in adverse effects among the groups analyzed, and 97% of the patients reported at least one adverse effect. Adverse effects included nausea, fatigue, vomiting, diarrhea, constipation, bone pain, urinary tract infection and peripheral edema.\(^8\) (A)

Then, another study with a slightly larger casuistry (122 patients) was conducted to evaluate the efficacy and safety of different dosages of Ra223. The doses administered were 25 kBq/kg in 41 patients, 50 kBq/kg in 39 patients and 80 kBq/kg in 42 patients, each of them undergoing a protocol of three applications every 4 weeks. The study demonstrated that dosages up to 80 kBq/Kg are safe. Ninety-two per cent (92%) of the patients had at least one adverse effect: diarrhea (21%), nausea (16%) and anemia (14%). There were no differences among the groups regarding survival, bone events, pain reduction or hematological events.\(^7\) (A)

In the ALSYMPCA study (N=921), the overall number of adverse and hematological effects was lower in patients treated with Ra223 (93%) compared to placebo (96%), with 47% serious events in the first and 60% in the latter group. The number of grade 3 or 4 adverse hematological effects was not significantly higher in the group treated with Ra223.\(^5\) (A)

Subgroup analysis of ALSYMPCA patients stratified by prior docetaxel use showed that the incidence of grade 3 or 4 anemia and neutropenia was similar between Ra223 and placebo, regardless of previous use of docetaxel.\(^6\) (A)
However, previous use of docetaxel led to a greater number of hematological adverse events in both Ra223 and placebo patients. However, grade 3 and 4 myelosuppression rates were low, with differences only in thrombocytopenia rates. In addition, previous use of docetaxel did not influence the number of non-hematological events.6 (A)

The main non-hematological adverse events reported in the studies were diarrhea, constipation, vomiting, nausea, fatigue, bone pain and peripheral edema.3,5,6,9,10 (A)

MARKERS
Evaluating the different dosages of Ra223 (25, 50 and 80 kBq/kg) in a total of 122 patients, there was a better alkaline phosphatase (AP) and prostate specific antigen (PSA) response in the groups receiving the highest doses (50 and 80 kBq/kg). No patient in the 25 kBq/kg group achieved a 50% reduction in PSA.9 (A)

In the ALSYMPCA study, there was a significant decline in AP and a longer time interval for elevation of this marker in patients treated with Ra223 compared to placebo. There was also a significant reduction of PSA in the Ra223 (16%) versus placebo (6%) group, in addition to a longer time interval to raise this parameter.5 (A)

In both studies described above, the AP and PSA values were analyzed after 12 weeks and the reduction was considered significant if greater than 30% of the initial value. This longer time to increase AP and PSA also occurred in the Ra223 group compared to placebo, regardless of previous docetaxel use (p<0.05).6 (A)

IMPROVEMENT OF PAIN AND QUALITY OF LIFE
A study with 100 mCRPC patients aimed at evaluating different single doses of Ra223 (5, 25, 50 and 100 kBq/kg) and had as primary outcome improvement of pain within 16 weeks after treatment. In this study, the groups receiving the highest Ra223 dosages (50 and 100 KBq/Kg) required less of other forms of analgesia for pain control than the groups receiving lower Ra223 dosages (5 and 25 kBq/kg).6 (A)

In the analysis of pain reduction alone among the different doses of Ra223 (25, 50 and 80 kBq/kg) given to 122 patients, there was a tendency for better results using 50 kBq/kg.9 (A) Despite the dose-response effect on pain reduction, there is no such analysis compared to placebo.

A subgroup analysis of patients from the ALSYMPCA study evaluated the improvement of quality of life. More patients treated with Ra223 showed improvement in quality of life assessment tests compared to patients treated with placebo (29.2% versus 18.5%; p=0.004).10 (A)

HOSPITALIZATION RATE
Another study evaluated the hospitalization rate within the 12 months following treatment with Ra223 compared to placebo-treated patients. Patients receiving Ra223 had a lower hospitalization rate than those treated with placebo (37% and 45.5%, respectively), regardless of whether a skeletal event occurred. In addition, the number of days of hospitalization in the Ra223 group was lower than in the placebo group (4.4 versus 6.6 days; p=0.004).11 (A)

EVIDENCE SUMMARY
We were able to perform a meta-analysis of two outcomes studied: survival and bone event. The other outcomes could not be investigated by meta-analysis due to the lack of necessary data or use of the same population in different studies.

SURVIVAL
Two studies4,5 (A) totaling 985 patients (647 in the Ra223 group and 338 in the placebo group) were included in this analysis. In this comparison, at 0% heterogeneity, there was a 10% decline in mortality (95CI 4-16) in favor of Ra223 treatment.12 (A) Thus, 10 patients need to be treated to avoid one death compared to no treatment (Figure 1).

BONE EVENTS
Two studies were included in the analysis5,7 (A) totaling 985 patients (647 treated with radium-223 and 338 with a placebo). In this comparison there is a non-significant reduction in the risk of bone events of 5% (95CI -1-11) in favor of treatment with Ra223 and heterogeneity is 0%. This means that there is no significant difference (p<0.05) in the risk of bone events when comparing treatment and non-treatment with radio-223 (Figure 2).

RECOMMENDATION
Ra223 is effective for the treatment of patients with mCRPC, with a reduction in mortality of 10% and an increase in mean survival over 3 months. There is no reduction in the number of bone events in these patients and no improvement in pain was observed except for the dose-response aspect.

Other benefits have been demonstrated, such as improved quality of life, increased time to skeletal events, reduced hospitalization and effect on markers such as PSA and AP.

The most common adverse events are both hematologic (anemia, neutropenia and thrombocytopenia) and non-hematological (diarrhea, constipation, vomiting, nausea, fatigue, bone pain and peripheral edema).
Treatment with six doses of 55 kBq/Kg of intravenous Ra223 injections every 30 days is recommended for patients with mCRPC and bone metastases.

**DISCUSSION AND PERSPECTIVES**

At the moment only five other medications, in addition to Ra223, which produce a demonstrated increase in survival in patients with mCRPC (docetaxel, cabazitaxel, abiraterone, enzalutamide, sipuleucel-T) are available. In view of this scenario, Ra223 stands out as a treatment with few contraindications and acceptable adverse effects, and an excellent option for mCRPC patients.

Although the studies presented here use a dose of 50 kBq/kg, the commercial dose was adjusted to 55 kBq/kg to meet the standardization criteria.13(D)

Only one study carried out re-treatment with Ra223 in mCRPC patients.14(B) Although it is a possibility, since the study showed safety, we do not recommend repeating the treatment until further studies are performed.

Studies are being conducted to validate the concomitant use of Ra223 with other therapies. We highlight the combination of Ra223 treatment with enzalutamide (phase III studies), abiraterone (phase II: NCT02097303), denosumab (phase II: NCT02366130), bicalutamide (phase II: NCT02582749) and radiotherapy (phase II: NCT02484339). In addition, studies in asymptomatic patients are being performed (NCT03002220).

Ra223 is also being studied to treat other diseases such as osteosarcoma (NCT01833520), multiple myeloma (NCT02928029) and breast cancer (phase II: NCT02258451).

As soon as these studies are available, we will update this guideline.

**CONFLICT OF INTEREST**

The authors state that there is no conflict of interest regarding this review.

**REFERENCES**


Annex I

Structured question

- P – Patients with prostate cancer resistant to castration and bone metastases.
- I – Intravenous therapy with radium-223.
- C – Placebo.
- O – Benefit or harm.

Search strategy

PubMed-Medline

- #1 - (Prostate Neoplasms OR Prostate Neoplasm OR Prostatic Neoplasm OR Prostate Cancer OR Prostate Cancers OR Prostatic Cancer OR Prostatic Cancers)
- #2 - (radium OR Xofigo OR Ra 223)
- #3 - random

1st RETRIEVAL = #1 AND #2 AND #3 = 99

Articles retrieved

Ninety-nine (99) articles were retrieved. Of these, 19 were selected by title and 11 by summary. After a critical analysis by three nuclear physicians, 13 studies were selected, using as inclusion criteria randomized clinical trials, greater strength of evidence and outcomes pertinent to the clinical doubt in question. The reason for excluding the other texts was that they were not randomized studies.

The scientific database consulted was Medline via Pubmed. A manual search was performed based on references of the reviews (narrative or systematic), as well as the selected studies.

Inclusion criteria for selected studies

Increased survival was the main outcome analyzed in this guideline; however, during its elaboration, it was possible to evaluate other outcomes, which are also presented.

According to study design

The studies included in this guideline were classified according to the Jadad score. According to this classification, studies with Jadad less than three are inconsistent, while those with a score greater than three are considered consistent.

Language

We included studies available in Portuguese, English or Spanish.

According to publication

Only full-text studies were considered for critical assessment.

Exposure of results

For results with available evidence, the population, intervention, outcomes, presence or absence of benefit and/or harm and controversies will be defined in a specific manner, whenever possible.

Recommendation

The recommendations will be elaborated by the authors of the review, with the initial characteristic of synthesis of the evidence, and later validated by all the authors who participate in the elaboration of this Guideline.

The grade of recommendation stems directly from the available strength of included studies, according to the Oxford scale, and the GRADE system.